<b>Conclusion:</b> The therapeutic effect of tolvaptan was reasonable as the gold standard for ADPKD treatment, while somatostatin analogs also showed notable efficacy in inhibiting TKV growth. The gene discussed is SST; the disease is autosomal dominant polycystic kidney disease.